A new head-to-head study reveals tirzepatide achieves 47% more weight loss than semaglutide in people with obesity but without diabetes, highlighting its superior effectiveness and cardiometabolic ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

Tirzepatide promoted greater weight loss in individuals with obesity than semaglutide in a clinical trial that compared the ...

Novo Nordisk is parting ways with its CEO Lars Fruergaard Jørgensen after the two parties mutually agreed that a change of ...

It was the first head-to-head comparison of the injectable GLP-1 medications semaglutide and tirzepatide, which are sold under the brand names Wegovy and Zepbound for weight loss. Roughly 750 ...

KATIE Price has sparked concern after she looked slimmer than ever in her latest Instagram post. The star, 47, has been bombarded with messages from fans fearing for her slender figure in her ...

In study after study, injected GLP-1 weight loss medications appear to work better on average for women than they do for men.

Trials have confirmed the efficacy of GLP-1 RAs in achieving clinically sustained weight loss in people with obesity without diabetes.

It's a look at these medicines that are used to treat obesity and it's a head-to-head comparison ... The two medications are tirzepatide and semaglutide. The semaglutide is what's known as ...